MRPL12 and hepatocellular carcinoma: The above results showed that MRPL12 downregulation is the key factor for lefamulin to sensitize HCC to sorafenib, and ILF3 is the direct target of lefamulin, we wondered whether lefamulin reduced MRPL12 expression in an ILF3‐dependent manner.